» Articles » PMID: 15100704

Evidence of Association Between Smoking and Alpha7 Nicotinic Receptor Subunit Gene in Schizophrenia Patients

Overview
Date 2004 Apr 22
PMID 15100704
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

A number of studies have suggested that the alpha-7-nicotinic receptor D15S1360 polymorphism is associated with schizophrenia and a deficiency in the normal inhibition of the P50 auditory-evoked response. Schizophrenia patients and some of their unaffected relatives show a failure of inhibition in their 50-ms response to the second of a pair of tones. Biochemical studies have suggested that the alpha7 nicotinic acetylcholine receptor is involved in this sensory gating deficit. Furthermore, high-dose nicotine transiently normalizes the abnormality in P50 inhibition in schizophrenic patients and in their relatives. Schizophrenic patients are unusually heavy smokers, and up to 85% of hospitalized schizophrenic patients smoke. This rate is three times higher than the general population, and may represent an attempt to self-medicate through this pathophysiologic mechanism. Despite schizophrenics' extremely heavy nicotine use, nicotinic receptor genes have not been previously investigated in relation to smoking in schizophrenia. In this study, we hypothesized that the D15S1360 marker is associated with smoking in patients with schizophrenia. We found an association between the homozygous 113 bp allele and smoking risk (chi2=10.37, 3 df, p=0.015). Although this novel finding requires replication, it suggests that further study into the relationship between schizophrenia and nicotine system genes is warranted.

Citing Articles

mGluR5 receptor availability is associated with lower levels of negative symptoms and better cognition in male patients with chronic schizophrenia.

Regio Brambilla C, Veselinovic T, Rajkumar R, Mauler J, Orth L, Ruch A Hum Brain Mapp. 2020; 41(10):2762-2781.

PMID: 32150317 PMC: 7294054. DOI: 10.1002/hbm.24976.


Nicotine consumption during the prodromal phase of schizophrenia - a review of the literature.

Gogos A, Skokou M, Ferentinou E, Gourzis P Neuropsychiatr Dis Treat. 2019; 15:2943-2958.

PMID: 31802874 PMC: 6801495. DOI: 10.2147/NDT.S210199.


Neurobiological Determinants of Tobacco Smoking in Schizophrenia.

Lucatch A, Lowe D, Clark R, Kozak K, George T Front Psychiatry. 2018; 9:672.

PMID: 30574101 PMC: 6291492. DOI: 10.3389/fpsyt.2018.00672.


Competitive docking model for prediction of the human nicotinic acetylcholine receptor α7 binding of tobacco constituents.

Ng H, Leggett C, Sakkiah S, Pan B, Ye H, Wu L Oncotarget. 2018; 9(24):16899-16916.

PMID: 29682193 PMC: 5908294. DOI: 10.18632/oncotarget.24458.


Does chronic nicotine consumption influence visual backward masking in schizophrenia and schizotypy?.

Shaqiri A, Willemin J, Sierro G, Roinishvili M, Iannantuoni L, Rurup L Schizophr Res Cogn. 2017; 2(2):93-99.

PMID: 29114459 PMC: 5609643. DOI: 10.1016/j.scog.2015.04.006.